1Burgos K, Malenica I, Metpally R, et al. Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology[J]. PLoS One, 2014,9(5):e94839.
2Shinohara M, Fujioka S, Murray ME, et al. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological fea- tures in sporadic and familial Alzheimer's disease[J].Brain, 2014,137 (Pt 5):1533-1549.
3Wang J, Bi W, Cheng A, et al. Targeting multiple pathogenic mecha- nisms with polyphenols for the treatment of Alzheimer's disease-experi- mental approach and therapeutic implications[J].Front Aging Neurosci, 2014,14(6):42.
4Oh H, Jagust WJ. Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid [J].J Neurosci, 2013,33(47): 18425- 18437.
5Kalimo H, Lalowski M, Bogdanovic N, et al. The Arctic AI3PP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.
6Colurso GJ, Nilson JE, Vervoort LG. Quantitative assessment of DNA fragmentation and beta-arnyloid deposition in insular cortex and mid- frontal gyms from patients with Alzheimer's disease[J].Life Sci,2003,73 (14):1795-803.
7Bamwell E, Padmaraju V, Baranello R, et al. Evidence of a novel mech- anism for partial /-seeretase inhibition induced paradoxical increase in secreted amyloid 13 protein[J].PLoS One,2014,9(3):e91531.
8Hampel H, Lista S. Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease[J]. Alzheimers Res Ther, 2013,5(2):11.
9Kim CB, Choi YY, Song WK, Song KB. Antibody-based magnetic nanopartiele immunoassay for quantification of Alzheimer's disease pathogenic factor[J].J Biomed Opt,2014 , 19(5):051205.
10Chu J, Li JG, Praticb D. Zileuton improves memory deficits, amyloid and tan pathology in a mouse model of Alzheimer's disease with plaques and tangles[J].PLoS One, 2013,8(8):e70991.
